Cadrenal Therape Stock Price, News & Analysis

Cadrenal Therapeutics (NASDAQ:CVKD) is pursuing underserved anticoagulation patients with a three‑pillar pipeline targeting chronic, acute, and immune‑mediated thrombosis.

Key elements: a Phase 3‑ready vitamin K antagonist tecarfarin designed for kidney‑impaired and dialysis patients; an acquired Factor XIa inhibitor portfolio for acute hospital care; and VLX‑1005, a Phase 2 12‑LOX inhibitor for heparin‑induced thrombocytopenia with Orphan Drug and Fast Track designations.

The company positions this asset mix as a purpose‑built platform to address high‑risk patients where existing anticoagulants perform poorly.

Cadrenal Therapeutics (Nasdaq: CVKD) said management, including CEO Quang X. Pham, will hold partnering and investor meetings during the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026. The company highlighted two 2025 acquisitions and stated its focus on the $40 billion anticoagulation market.

Cadrenal's pipeline items cited: VLX-1005 (phase 2 IV 12-LOX inhibitor; ODD and Fast Track for HIT), tecarfarin (phase 3-ready oral VKA; ODD and Fast Track for ESKD with AFib; ODD for LVAD in collaboration with Abbott), and frunexian (phase 2-ready IV FXIa inhibitor for acute care).

Cadrenal Therapeutics (NASDAQ:CVKD) announced a quiet but material expansion of its clinical platform on December 12, 2025, advancing trial preparation, manufacturing, and clinical leadership.

The company added a Factor XIa program to target acute hospital anticoagulation and acquired VLX-1005, a Phase 2 asset with Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia (HIT).

Management positions Cadrenal with complementary chronic and acute assets—tecarfarin for chronic care, Factor XIa for hospital use, and VLX-1005 for HIT—potentially shifting investor perception if clinical progress becomes visible.

Cadrenal Therapeutics (NASDAQ:CVKD) is expanding from a single-asset microcap into a multi‑asset anticoagulation platform addressing a $40 billion market.

The company acquired a Factor XIa portfolio for hospital use, bought VLX-1005 (Phase 2) with Orphan Drug and Fast Track designations for heparin‑induced thrombocytopenia, and is advancing tecarfarin toward Phase 3 readiness for difficult‑to‑treat chronic anticoagulation patients.

Management says these moves create chronic and acute care reach, multiple mechanistic approaches, and near‑term clinical catalysts that could prompt a market revaluation.

Cadrenal Therapeutics (NASDAQ: CVKD) announced on Dec 11, 2025 the acquisition of VLX-1005 and related 12-LOX assets from Veralox Therapeutics, adding a late-stage, first-in-class small‑molecule 12‑lipoxygenase inhibitor for heparin‑induced thrombocytopenia (HIT).

VLX-1005 has U.S. Orphan Drug and Fast Track designations, completed two Phase 1 studies showing favorable tolerability, and interim Phase 2 data reporting reductions in thromboembolic events. The release cites a $40 billion global anticoagulation market and an estimated $1 billion HIT market in the US and EU. Veralox may receive upfront, milestone payments and royalties upon commercialization.

Cadrenal Therapeutics (Nasdaq: CVKD) announced on December 1, 2025 the immediate appointment of Lee Scott Golden, M.D., as an independent member of its Board of Directors. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics and has over 25 years of industry experience across cardiovascular and hematologic drug development.

His background includes senior medical roles at Espero BioPharma and Gemphire, leadership at Pfizer, Actelion, Eisai, and Mesoblast, and advisory work in coagulation sciences. Management highlighted his expertise in late-stage clinical development and regulatory pathways as aligned with Cadrenal’s goal to advance tecarfarin and its broader anticoagulation pipeline.

Cadrenal Therapeutics (Nasdaq: CVKD) reported Q3 2025 results and clinical and corporate updates on November 10, 2025. Key development milestones include cGMP manufacturing completion for tecarfarin, ongoing activities supporting a single-site U.S. Phase 2 tecarfarin study in LVAD patients with Abbott, and investigator discussions for a potential multi-site Phase 2 dialysis study.

In September 2025 Cadrenal acquired eXIthera assets, adding a Phase 2-ready IV Factor XIa inhibitor, frunexian, aimed at acute care and device-related thrombosis settings. Q3 financials: R&D $0.7M, G&A $2.0M, net loss $2.7M, cash and equivalents $3.9M, and ~2.1M shares outstanding.

Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on anticoagulation therapy, will participate in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025.

The company's webcast presentation is scheduled for 3:30 p.m. ET and will be accessible through the conference website. Management will also be available for one-on-one meetings with investors throughout the event.

Cadrenal Therapeutics (Nasdaq: CVKD) has acquired eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors, significantly expanding its anticoagulation pipeline. The acquisition includes frunexian, a Phase 2-ready intravenous Factor XIa inhibitor, and EP-7327, an IND-ready oral Factor XIa inhibitor.

The deal positions Cadrenal as the only company developing both a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, targeting the $38 billion global anticoagulation market. The acquisition terms include milestone payments up to $15 million and future royalties. Sichuan Haisco Pharmaceuticals maintains rights to frunexian in China, with Cadrenal receiving royalties on future Chinese sales.